6-Mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity

Cancer Investigation

Volumn 25, Issue 2, 2007, Pages 117-123

  Umrethia, Manish ^a   Ghosh, Pradip Kumar ^a   Majithya, Rita ^a   Murthy, R S R ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

6 Mercaptopurine; Biodistribution studies; Liposomes; Pharmacokinetic

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; LIPOSOME; MACROGOL 2000; MERCAPTOPURINE; PHOSPHATIDYLCHOLINE; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; FEMALE; FILM; HUMAN; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; THERMOSTABILITY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; UREA BLOOD LEVEL;

6-MERCAPTOPURINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; KIDNEY; LEUKEMIA; LIPOSOMES; LIVER; MALE; RATS; RATS, INBRED STRAINS; TISSUE DISTRIBUTION;

EID: 34247157805     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701224862     Document Type: Article

References (35)

1. Sharma, A.; Sharma, U.S. Liposomes in drug delivery: progress and limitations. Int J. Pharm 1997, 154, 123-140.
2. Labana, S.; Pandey, R.; Sharma, S.; Khuller, G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicro. Agents 2002, 20, 301-304.
3. Van Hoesel, Q.; Steerenberg, P.A.; Crommelin, D.J.; Vandijk, A.; Vanoort, W.; Klein, S. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor-activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rats. Cancer Res. 1984, 44, 3698-3705.
4. Namba, Y.; Oku, N. Liposomal applications to cancer therapy, J. Bioact. Compat. Polym. 1993, 8, 158-177.
5. Janine, E.; Friedman, J.M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002, 65, 240-261.
6. Federico, I.; Antonello, D.P.; Barbara, L. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother. Pharmacol. 1996, 37, 409-414.
7. Hayder, S.; Lafolie, P.; Bjork, O.; Peterson, C. 6-Mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Ther. Drug Monit. 1989, 11, 617-622.
8. Lafolie, P.; Hayder, S.; Bjork, O.; Ahstrom, L.; Liliemark, J.; Peterson, C. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukemia and non-Hodgkin's lymphoma. Acta. Paediat. Scand. 1986, 75, 797-803.
9. Riccardi, R.; Balis, F.; Ferrara, P.; Lasorella, A.; Poplack, D.; Mastrangelo, R. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 1986, 3, 319-324.
10. Sulh, H.; Koren, G.; Whalen, C.; Soldin, S.; Zipursky, A.; Greenberg, M. Pharmacokinetic determinations of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 1986, 40, 604-609.
11. Zimm, S.; Collins, J.M.; Riccardi, R.; O'Neill, D.; Narang, P.K.; Chabner, B. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N. Engl. J. Med. 1983, 308, 1005-1009.
12. Arulsudar, N.; Subramanian, N.; Mishra, P.; Murthy, R.S.R. Preparation, Characterization, and biodistribution study of Technetium-99m-labled leuprolide acetate loaded liposomes in ehrlich ascites tumor bearing mice, AAPS Pharm. Sci. 2004, 6 (1), article 5, 1-12.
13. Takeuchi, H.; Kojima, H.; Yamamoto, H.; Kawashima, Y. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J. Controlled Rel. 2001, 75, 83-91.
14. Oku N. Anticancer therapy using glucuronate modified longcirculating liposomes, Adv. Drug Del. Rew. 1999, 40, 63-73.
15. Herman, E.H.; Rahman, A.; Ferrans, V.J.; Vick, J.A.; Schein, P.S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983, 43, 5427-732.
16. Gabizon, A.; Catane, R.; Uziely, B. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54, 987-92.
17. Newman, M.S.; Colbern, G.T.; Working, P.K.; Engbers, C.; Amantea, M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 1999, 43, 1-7.
18. Gondal, J.A.; Preuss, H.G.; Swartz, R.; Rahman A. Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur. J. Cancer 1993, 29A, 1536-1542.
19. Ishida, T.; Iden, D.; Allen, T. A combinatorial approach to producing sterically stabilized immunoliposomal drugs. FEBS Lett. 1999, 460, 129-133.
20. Bangham, A.D.; Standish, M.M.; Watkins, J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13, 238-252.
21. Betagiri, G.V.; Jenkins, S.A.; Parsons, D.L. Stability of Liposomes. Liposomal Drug Delivery Systems, 10th Ed; Technomic Publications: Lancaster, 1993; 27-56.
22. Chalmers, A.H. A spectrophotometric method for the estimation of urinary azathioprine, 6-mercaptopurine, and 6-thiouric acid. Biochem. Med. 1975, 16 (6), 513-515.
23. Bhalerao, S.S.; Harshal, A.R. Preparation, optimization, characterization and stability studies of salicylic acid liposomes. Drug Dev. Ind. Pharm. 2003, 29 (4), 451-467.
24. 3 factorial 26-term logit model. Pharm. Dev. Tech. 2004, 9 (4), 369-378.
25. Gibaldi, M.; Perrier, D. Pharmacokinetics, Marcel Dekker: New York; 1982, 409-416.
26. Subramanian, N.; Murthy, R.S.R. Use of electrolyte induced flocculation technique for in-vitro steric stability of sterically stabilized liposomal formulation. Die Pharmazie 2004, 1, 69-74.
27. Sykes, E.; Woodburn, K.; Decker, D.; Kessel, D. Effects of cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer 1994, 70, 401-404.
28. Rowinsky, E.K.; Donehower, R.C. Paclitaxel (Taxol). N. Engl. J. Med. 1995, 332, 1004-1014.
29. Liebmann, J.; Cook, J.A.; Lipschultz, C.; Teague, D.; Fischer, J.; Mitchell, J.B. The influence of cremophor EL on the cell cycle effects of paclitaxel in human cell lines. Cancer Chemother. Pharmacol. 1994, 33, 331-339.
30. Federico, I.; Antonello, D.P.; Barbara. L. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother. Pharmacol. 1996, 37, 409-414.
31. Zimm, S.; Collins, J.M.; O'Neill, D.; Chabner, B.A.; Poplack, D.G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther. 1983, 34, 810-817.
32. Lennard, L.; Keen, D.; Lilleyman, J.S. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin. Pharmacol. Ther. 1986, 40, 287-292.
33. Lennard, L.; Lilleyman, J.S.; Van Loon, J.; Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990, 336, 225-229.
34. Lennard, L.; Lilleyman, J.S. Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. 1989, 7, 1816-1823.
35. Gabizon, G.; Papahadjopoulos, D. Liposomes formulation with prolonged circulation time in blood and enhance uptake by tumors. Pro. Nat. Acad. Sci. USA. 1988, 85, 6949-6953.